DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



High-resolution Imaging of Corneal Lesions With Optical Coherence Tomography (OCT) - A Pilot Study

Information source: Medical University of Vienna
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Corneal Abrasions; Corneal Infiltrates

Intervention: Optical Coherence Tomography (OCT) (Device); Slit lamp biomicroscopy (Other)

Phase: N/A

Status: Recruiting

Sponsored by: Medical University of Vienna

Overall contact:
Gerhard Garhoefer, MD, Phone: +43140400, Ext: 2981, Email: gerhard.garhoefer@meduniwien.ac.at

Summary

Corneal lesions such as corneal abrasions and corneal infiltrates are common in clinical practice. The current study seeks to investigate whether high-resolution OCT is suitable for imaging of these corneal lesions. The present study has the character of a pilot study and the results are intended to be used to develop a standardized protocol for imaging and analysis of these corneal lesions. Based on this protocol, further studies investigating the pathophysiology of corneal lesions or evaluating therapeutic success can be planned.

Clinical Details

Official title: High-resolution Imaging of Corneal Lesions With Optical Coherence Tomography (OCT) - A Pilot Study

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome: Imaging of corneal abrasions and infiltrates

Secondary outcome:

Size and depth of corneal lesions as assessed with high-resolution OCT

Slit lamp biomicroscopy with fluorescein staining

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Men and women aged over 18 years

- Newly diagnosed corneal abrasion or corneal infiltrate

Exclusion Criteria:

- Recurrent corneal erosion

- Participation in a clinical trial in the previous 3 weeks

- Presence of any abnormalities preventing reliable measurements as judged by the

investigator

- Any contraindication for topical application of Novain 0. 4% eye drops for topical

anesthesia or of Minims-Fluorescein Sodium eye drops for fluorescein staining

- Pregnancy, planned pregnancy or lactating

Locations and Contacts

Gerhard Garhoefer, MD, Phone: +43140400, Ext: 2981, Email: gerhard.garhoefer@meduniwien.ac.at

Department of Clinical Pharmacology, Medical University of Vienna, Vienna 1090, Austria; Recruiting
Gerhard Garhoefer, MD, Phone: +43140400, Ext: 2981, Email: gerhard.garhoefer@meduniwien.ac.at
Katarzyna Napora, MD, Principal Investigator
Additional Information

Starting date: July 2013
Last updated: November 12, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017